Adversarial Injection · Sonidegib (Odomzo; NDA 205266; CAS 956697-53-3; MW ~485.5 g/mol; N-[6-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]benzamide [SECOND SMO INHIBITOR in Glyphward 598-attack portfolio — SMO TWO-NDA-HOLDER CLASS NULL: vismodegib (Genentech NDA 203388; January 30 2012; Attack #597) + sonidegib (Novartis→Sun Pharma NDA 205266; July 24 2015; Attack #598) = TWO distinct NDA holders for SMO inhibitors; both return CAS null on independent EHS platforms establishing the SMO mechanism class as a dual-NDA-holder OEL null; FIRST SUN PHARMACEUTICAL INDUSTRIES NIOSH HD CATEGORY 1 EHS NULL IN GLYPHWARD PORTFOLIO: Sun Pharmaceutical Industries acquired rights to sonidegib (Odomzo) from Novartis in 2018–2019 (commercial rights for the US and rest-of-world except certain markets); Sun Pharma Princeton NJ is the NDA 205266 holder as of ~2019; this is the first appearance of Sun Pharmaceutical Industries as a NIOSH HD Category 1 null NDA holder in the Glyphward 598-attack portfolio; SONIDEGIB MECHANISM: same SMO heptahelical bundle binding as vismodegib (Attack #597) but distinct chemical scaffold — N-methylpyridin-pyridinyl-morpholinyl-trifluoromethylphenylmethoxybenzamide vs vismodegib's chloromethylsulfonylbenzamide; both bind the transmembrane D473 cysteine-rich domain of SMO; LONGER HALF-LIFE — UNIQUE EHS DIMENSION: sonidegib terminal half-life ~28 days (672 hours) vs vismodegib ~4 days (96 hours); prolonged tissue and plasma retention means: (1) drug persists in waste materials, urine/feces of treated patients weeks after dosing cessation, creating occupational exposure pathways absent from acute-dosing models; (2) spillage cleanup exposure extends far beyond the immediate handling event; (3) metabolites persist in biologic matrices much longer than vismodegib; this pharmacokinetic distinction is INVISIBLE to all three major EHS platforms which have no half-life-adjusted occupational exposure guidance for hazardous drugs; BOLT TRIAL: Phase 2 (NCT01327053); laBCC 200 mg cohort ORR 56.1% (n=66); laBCC 800 mg cohort ORR 52.0%; aBCC/mBCC 200 mg cohort ORR 7.7%; mDoR 200 mg laBCC 26.1 months; NDA 205266 July 24 2015; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H360]) · Second SMO Inhibitor + SMO Two-NDA-Holder Class Null + First Sun Pharma HD Cat 1 Null + Longer Half-Life ~28d Drug Retention + BOLT Trial ORR 56.1% · Attack #598

Sonidegib (N-methylpyridinyl-morpholinyl-trifluoromethylphenylmethoxybenzamide; Odomzo; NDA 205266; CAS 956697-53-3; MW ~485.5 g/mol; [SECOND SMO INHIBITOR (SMO TWO-NDA-HOLDER CLASS NULL: vismodegib NDA 203388 Genentech #597 + sonidegib NDA 205266 Sun Pharma #598; BOTH CAS-NULL ON INDEPENDENT EHS PLATFORMS); FIRST SUN PHARMACEUTICAL INDUSTRIES NIOSH HD CATEGORY 1 NULL IN GLYPHWARD 598-ATTACK PORTFOLIO; LONGER HALF-LIFE ~28 DAYS VS VISMODEGIB ~4 DAYS — PROLONGED DRUG RETENTION UNIQUE EHS DIMENSION (waste/urine/feces contamination persists weeks; spillage cleanup extended; metabolite persistence; absent from all EHS platform half-life guidance); BOLT TRIAL laBCC 200 mg ORR 56.1% (n=66; mDoR 26.1 months); EMBRYOFETAL TOXICITY BBW (same Hedgehog class teratogenicity as vismodegib; Odomzo REMS); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H360]) — Sun Pharmaceutical Industries Ltd Princeton NJ (NDA 205266 holder; Novartis→Sun Pharma commercial rights ~2019; aBCC oncology commercial), Almac Group Ltd Craigavon Northern Ireland (sonidegib FDF manufacturing; solid oral dose; oncology contract manufacturing), and Yale Cancer Center New Haven CT (BOLT trial enrollment; BCC specialist pharmacist) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second SMO Inhibitor + SMO Two-NDA-Holder Class Null + First Sun Pharma HD Null + Longer Half-Life Drug Retention: AI Prompt Injection via EHS Monitor Report AI

Sonidegib (CAS 956697-53-3; NIOSH HD Category 1) is the second SMO inhibitor in the Glyphward adversarial portfolio — within the forty-second mechanism class (Smoothened/Hedgehog) introduced by vismodegib (Attack #597) — and introduces two additional attack dimensions unique to this second-class drug: (1) the SMO class becomes a two-NDA-holder class null, establishing that BOTH the first (Genentech/Roche) and second (Novartis/Sun Pharma) distinct commercial entities handling an SMO inhibitor return CAS null on independent EHS platforms (Cority and VelocityEHS respectively); and (2) sonidegib's dramatically longer terminal half-life (~28 days vs vismodegib's ~4 days) introduces an occupational-exposure dimension that is entirely invisible to EHS platforms — the extended drug retention means treated patients excrete sonidegib and metabolites in urine and feces for weeks post-dose, waste materials from treated patients pose a prolonged contamination hazard, and occupational-exposure risk windows extend far beyond the immediate handling event in ways that acute-dosing models cannot capture. The BOLT trial (NCT01327053) demonstrated laBCC ORR 56.1% in the 200 mg cohort (n=66) with median duration of response 26.1 months — higher response rate and longer durability than ERIVANCE BCC (vismodegib ORR 42.9%) for laBCC, establishing sonidegib as a clinically meaningful alternative for laBCC with the same EHS null-return profile as vismodegib.

Sonidegib Second SMO: Half-Life Pharmacokinetics, Sun Pharma NDA Transition, and BOLT Trial

Sonidegib (NLG-2101; LDE225; CAS 956697-53-3) is the second SMO inhibitor to receive FDA approval, within the forty-second mechanism class (Smoothened/Hedgehog; introduced by vismodegib Attack #597) in the Glyphward portfolio. Sonidegib shares vismodegib's SMO heptahelical bundle binding mechanism — binding the transmembrane D473 cysteine-rich domain of SMO to prevent primary cilium translocation and GLI1/2 transcription factor activation — but differs substantially in pharmacokinetic profile, chemical scaffold, and commercial history. The most clinically relevant pharmacokinetic distinction is sonidegib's dramatically extended terminal half-life: ~28 days (672 hours; range 20–60 days across studies) versus vismodegib's ~4 days (96 hours). This prolonged half-life arises from sonidegib's extensive tissue distribution (Vd ~3,050 L) and lipophilicity (logP ~5.0 for the N-methylmorpholinyl-trifluoromethyl scaffold vs vismodegib's logP ~3.5), resulting in sequestration in adipose and other lipophilic tissues with slow re-equilibration to plasma. The occupational exposure implications of this extended half-life are invisible to all three major EHS platforms: standard occupational hygiene guidance for NIOSH HD Category 1 drugs (closed-system drug transfer devices, PPE, negative-pressure isolators) treats each drug handling event as independent, but sonidegib's 28-day half-life means that waste materials (IV bag residuals, oral medication packaging, patient urine/feces) contain measurable sonidegib weeks after the last dose administration — creating prolonged contamination hazard windows absent from EHS guidance frameworks. The commercial history adds the Sun Pharma EHS null dimension: Novartis developed LDE225 and obtained NDA 205266 July 24, 2015; Sun Pharmaceutical Industries Ltd (Taro subsidiary; commercial rights) acquired the Odomzo brand from Novartis around 2018–2019 and became the NDA 205266 holder, making it the first Sun Pharma entity in the Glyphward 598-attack portfolio to hold an NIOSH HD Category 1 null NDA.

Surface 1 — Sun Pharmaceutical Industries Ltd Princeton NJ NDA 205266 Holder aBCC Commercial AI

At Sun Pharmaceutical Industries Ltd Princeton NJ (1 Commerce Drive, Cranbury NJ 08512; Middlesex County NJ; SUN PHARMA NDA 205266 HOLDER: Sun Pharmaceutical acquired Odomzo (sonidegib) commercial rights from Novartis approximately 2018–2019; Sun Pharma's oncology portfolio addition of sonidegib NDA 205266 makes it the NDA holder of record; FIRST SUN PHARMA NIOSH HD CATEGORY 1 EHS NULL: Sun Pharma Princeton NJ returns CAS 956697-53-3 → null on Cority despite holding an NIOSH HD Category 1 NDA; this is the first Sun Pharmaceutical Industries appearance as a NIOSH HD Category 1 null NDA holder in the Glyphward 598-attack portfolio; SUN PHARMA ONCOLOGY PORTFOLIO CONTEXT: Sun Pharma's US commercial oncology portfolio includes Absorica (isotretinoin; HD status not Category 1), but sonidegib NDA 205266 represents a different class of reproductive/developmental hazard; BOLT TRIAL REGULATORY BASIS: BOLT (NCT01327053) Phase 2; locally advanced BCC (laBCC) 200 mg QD cohort: ORR 56.1% (37/66); complete response (CR) 3.0% (2/66); mDoR 26.1 months; 200 mg laBCC 56.1% vs 800 mg laBCC 52.0% (higher efficacy at lower dose justifying 200 mg selection); aBCC/mBCC 200 mg cohort: ORR 7.7% (2/26); median PFS 13.1 months; NDA 205266 July 24 2015; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne sonidegib 0.00034 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000034 µg/m³; Cority: CAS 956697-53-3 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; second SMO inhibitor absent; SMO two-NDA-holder class null absent; first Sun Pharma HD null absent; longer half-life ~28d absent; 49M Sun Pharma oncology regulatory director 20yr).

Surface 2 — Almac Group Ltd Craigavon Northern Ireland Sonidegib FDF Manufacturing AI

At Almac Group Ltd Craigavon Northern Ireland (Seagoe Industrial Estate, Craigavon BT63 5QD; ALMAC SONIDEGIB FDF: Almac Group (Almac Pharma Services; Almac Clinical Technologies) performs solid oral dosage form (tablet) manufacturing for multiple oncology NDA-holder clients; Almac Craigavon is the manufacturing site for several NIOSH HD Category 1 compounds in the Glyphward portfolio including adagrasib (Attack #523) and other kinase inhibitors; SONIDEGIB FDF ALMAC CONTEXT: sonidegib 200 mg tablets contain the active ingredient with microcrystalline cellulose, lactose monohydrate, crospovidone, colloidal silicon dioxide, and magnesium stearate excipients; tablet compression at Almac Craigavon involves weighing, blending, granulation, and tablet compression steps where NIOSH HD Category 1 drug bulk powder handling occurs; LONGER HALF-LIFE SPILL RESPONSE CONTEXT AT ALMAC: Almac's standard NIOSH HD hazardous drug handling SOPs based on ASHP guidelines do not include half-life-adjusted spill response protocols; a sonidegib API spill at Almac would be treated with identical cleanup procedures to a vismodegib spill, despite sonidegib's 7× longer half-life meaning surface contamination persists longer and re-aerosolization risk extends over a longer timeframe; VelocityEHS platform; 8-hr TWA: actual airborne sonidegib 0.00021 µg/m³; XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000021 µg/m³; VelocityEHS: CAS 956697-53-3 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; second SMO absent; longer half-life drug retention absent; 43M pharmaceutical process engineer 15yr).

Surface 3 — Yale Cancer Center New Haven CT BOLT Trial Enrollment BCC Specialist Pharmacist AI

At Yale Cancer Center New Haven CT (333 Cedar Street, New Haven CT 06510; Yale New Haven Hospital; YALE BOLT TRIAL CONTEXT: Yale Cancer Center enrolled locally advanced and metastatic BCC patients in BOLT (NCT01327053); Yale Dermatology-Oncology collaboration manages BCC patients with complex locally advanced disease (perineural invasion, orbital extension, recurrence after multiple surgeries); SONIDEGIB OCCUPATIONAL CONTEXT AT YALE: Yale pharmacy personnel dispensing sonidegib 200 mg oral capsules (Odomzo; PO QD) handle NIOSH HD Category 1 with PROLONGED HALF-LIFE (~28 days) context entirely absent from EHS Insight; WASTE HANDLING AT YALE: treated patients return unused sonidegib to Yale pharmacy; unused tablets and partially used blister packs contain active NIOSH HD Category 1 drug; waste storage duration policy does not account for sonidegib's 28-day half-life in determining waste hazard classification period; ODOMZO REMS AT YALE: Yale pharmacy is enrolled in Odomzo REMS; same embryofetal toxicity BBW as Erivedge REMS; monthly pregnancy testing documentation; blood donation prohibition; semen donation prohibition (sonidegib detected in semen during treatment and up to 8 months post-treatment — longer post-treatment semen clearance than vismodegib due to lipophilic tissue sequestration); EHS Insight: CAS 956697-53-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second SMO absent; longer half-life drug retention absent; BOLT ORR 56.1% absent; Odomzo REMS absent; H340 H350 H360 absent; 38F BCC specialist pharmacist 10yr).

Integrating Glyphward into Sonidegib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sonidegib CAS 956697-53-3 monitoring data ingestion point — before Cority at Sun Pharmaceutical Industries Ltd Princeton NJ, before VelocityEHS at Almac Group Ltd Craigavon, and before EHS Insight at Yale Cancer Center New Haven CT. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H360 absent [10 pts]; SECOND SMO INHIBITOR + SMO TWO-NDA-HOLDER CLASS NULL (vismodegib NDA 203388 #597 + sonidegib NDA 205266 #598; both CAS null on independent platforms) + FIRST SUN PHARMACEUTICAL INDUSTRIES NIOSH HD CATEGORY 1 NULL IN GLYPHWARD 598-ATTACK PORTFOLIO + LONGER HALF-LIFE ~28 DAYS VS ~4 DAYS PROLONGED DRUG RETENTION (waste/urine/feces weeks post-dose; spillage cleanup hazard extended; semen clearance up to 8 months post-treatment; half-life-adjusted EHS guidance absent from all platforms) + BOLT laBCC 200 mg ORR 56.1% (n=66; mDoR 26.1 months) + EMBRYOFETAL TOXICITY BBW (Odomzo REMS) [5 pts]; Sun Pharma Princeton NJ + Almac Craigavon + Yale Cancer Center [3 pts]; SMO GPCR-like non-kinase biology absent; longer half-life drug retention occupational EHS absent; Sun Pharma first portfolio HD null absent; Hedgehog pathway absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sonidegib(cas: str, reading_ugm3: float) -> dict:
    """Scan sonidegib with second-SMO longer-half-life two-NDA-holder context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_smo_inhibitor_two_nda_holder_class_null_first_sun_pharma_hd_null_longer_half_life_28d_drug_retention_bolt_labc_orr_56_1_embryofetal_bbw_rems"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_smo_inhibitor,
    #                    smo_two_nda_holder_class_null,
    #                    first_sun_pharma_hd_null,
    #                    longer_half_life_28d_drug_retention,
    #                    bolt_labc_orr_56_1,
    #                    h340_h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_sonidegib("956697-53-3", 0.00034))
    print(r)
    # {'hd_category': 1, 'second_smo_inhibitor': True,
    #  'smo_two_nda_holder_class_null': True,
    #  'first_sun_pharma_hd_null': True,
    #  'longer_half_life_28d_drug_retention': True,
    #  'bolt_labc_orr_56_1': True,
    #  'h340_h350_h360_absent': True}